natgillin/translations-raw huggingface dataset:
A catamaran boat (1) comprising: 
Katamaranski brod (1) koji sadrži:
said motor means (4a, 4b) comprise an azimuth thruster, provided on each catamaran craft (1a, 1b) at bow (2a, 2b); 
navedena pogonska sredstva (4a, 4b) sadrže azimut potisnik, koji se nalazi na svakom katamaranskom plovilu (1a, 1b) na pramcu (2a, 2b);
wherein said motor means (4a, 4b) and the direction means (5a, 5b) are provided along said median axes (x). 
pri čemu su navedena pogonska sredstva (4a, 4b) i sredstva za usmjeravanje (5a, 5b) predviđena duž navedenih središnjih osi (x).
aligning means (10a, 10b, 11a, 11b) adapted to make the first (1a) and the second (1b) craft coaxial; 
sredstva za poravnavanje (10a, 10b, 11a, 11b) prilagođena za osiguravanje da su prvo (1a) i drugo (1b) plovilo koaksijalno poravnata;
locking means (20a, 20b, 21a, 21b, 22a, 22b, 23a, 23b, 24a, 24b, 25, 26a, 26b, 27a, 27b) adapted to make the coupling of said first (1a) and second craft (1b) stable and rigid. 
sredstva za zaključavanje (20a, 20b, 21a, 21b, 22a, 22b, 23a, 23b, 24a, 24b, 25, 26a, 26b, 27a, 27b) prilagođena da osiguravaju da spajanje navedenog prvog (1a) i drugog plovila (1b) bude stabilno i kruto.
The catamaran boat (1) according to claim 4, characterized in that said locking means comprise a panel (20a, 20b) rotationally associated with each craft (1a, 1b) and adapted to rotate in order to be firmly fixed to the opposite craft (1b, 1a). 
Katamaranski brod (1) prema zahtjevu 4, naznačen time što navedena sredstva za zaključavanje sadrže ploču (20a, 20b) rotacijski povezanu sa svakim plovilom (1a, 1b) i prilagođenu da rotira kako bi se čvrsto pričvrstila na suprotno plovilo (1b, 1a).
The catamaran boat (1) according to claim 8, characterized in that said jaw hook (22a, 22b) comprises a hydraulic piston (27a, 27b) adapted to exert a force to the jaw in order to clasp said retaining element (25). 
Katamaranski brod (1) prema zahtjevu 8, naznačen time što navedena čeljust s kukom (22a, 22b) sadrži hidraulički klip (27a, 27b) koji je prilagođen da djeluje silom na čeljust s kukom da bi se pričvrstio navedeni zadržni element (25).
The method of claim 1, wherein in at least one site mapped to the center frame comprising the at least one blank, at least one user interface is deleted, edited, generated, moved, rearranged, and resized in a drag & drop manner. 
Metoda iz patentnog zahtjeva 1, gdje je u internet stranica koja je mapirana do URL adrese sa brojem najmanje jedno korisničko sučelje je obrisano, uređeno, generirano, pomaknuto, preraspoređeno, ili mu je promijenjena veličina na povuci i pusti (drag & drop) način.
R4C is selected from the group consisting of OH, -OC(=O)R"C and an optionally substituted O-linked amino acid; 
A je odabran iz skupine koju čine OH, -OC(=O)R"A i po izboru supstituirana O-vezana aminokiselina;
R9C, R10C, R12C and R13C are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl; 
A, R20A, R22A i R23A su neovisno odabrani iz skupine koju čine vodik, po izboru supstituiran C1-24 alkil i po izboru supstituiran aril;
R15C is selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl; 
A i R29A su neovisno odabrani iz skupine koju čine vodik, po izboru supstituiran C1-24 alkil i po izboru supstituiran aril;
A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof. 
Farmaceutski pripravak naznačen time što sadrži učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-43, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač, razrjeđivač, pomoćnu tvar ili njihovu kombinaciju.
IMPROVED DISMANTLABLE SELF-ASSEMBLY STRUCTURE according to the preceding claim, characterised in that the cut-outs (8) made in the lower part of the longitudinal members (1) are closed on the bottom by a tie-rod (9) that is flush with the bottom surface of the longitudinal member. 
RASTAVLJIVA SAMOSKLOPIVA STRUKTURA prema prethodnom zahtjevu, naznačena time, da su izrezi (8) napravljeni u donjem dijelu uzdužnih elemenata (1) zatvoreni na dnu pomoću vezne šipke (9) koja je u ravnini s donjom površinom uzdužnog člana.
IMPROVED DISMANTLABLE SELF-ASSEMBLY STRUCTURE according to claim 1, characterised in that once assembled the ends of the cross members (10) rest on the recess(7) and are flush with the bottom part of the longitudinal member provided with a thickening. 
RASTAVLJIVA SAMOSKLOPIVA STRUKTURA prema patentnom zahtjevu 1, naznačena time da, kada je jednom sklopljena, krajevi (10) poprečnih elemenata (2) su poravnati sa stranom (11) donjeg dijela (6) uzdužnog elementa koji ima zadebljanje.
wherein the cancer is a solid tumor, and wherein: 
gdje je rak čvrsti tumor, te gdje:
The method of claim 1, wherein the cancer is selected from lung cancer, breast cancer, liver cancer, ovarian cancer, gastric cancer, gastrointestinal cancer, gallbladder cancer, bladder cancer, glioblastoma, a sarcoma, melanoma, colorectal cancer and pancreatic cancer. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se rak bira između raka pluća, raka dojke, raka jetre, raka jajnika, raka želuca, gastrointestinalnog raka, raka žučnog mjehura, raka mokraćnog mjehura, glioblastoma, sarkoma, melanoma, kolorektalnog raka i raka gušterače.
The method of claim 1, wherein the characterized cell lines are selected from cell lines representative of the type of biological sample of claim 1, optionally wherein the characterized cell lines are non-small cell lung cancer cell lines, hepatocellular cell lines, or ovarian cell lines. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što okarakterizirane stanične linije se bira između staničnih linija reprezentativnih za tip biološkog uzorka u skladu s patentnim zahtjevom 1, gdje okarakterizirane stanične linije mogu biti stanične linije raka velikih stanica pluća, stanične linije jetrenih stanica ili stanične linije iz jajnika.
DISMANTLABLE SELF-ASSEMBLY STRUCTURE according to the preceding claim, characterised in that the cut-outs (8) made in the lower part of the longitudinal members (1) are closed on the bottom by a tie-rod (9) that is flush with the bottom surface of the longitudinal member. 
RASTAVLJIVA SAMOSKLOPIVA STRUKTURA prema prethodnom zahtjevu, naznačena time, da su izrezi (8) napravljeni u donjem dijelu uzdužnih elemenata (1) zatvoreni na dnu pomoću vezne šipke (9) koja je u ravnini s donjom površinom uzdužnog člana.
DISMANTLABLE SELF-ASSEMBLY STRUCTURE according to claim 1, characterised in that once assembled the ends (10) of the cross members (2) are flush with a side (11) of bottom part (6) of the longitudinal member provided with the thickening. 
RASTAVLJIVA SAMOSKLOPIVA STRUKTURA prema patentnom zahtjevu 1, naznačena time da, kada je jednom sklopljena, krajevi (10) poprečnih elemenata (2) su poravnati sa stranom (11) donjeg dijela (6) uzdužnog elementa koji ima zadebljanje.
Bag web according to claim 1 or 2, characterised in that the bag web includes two superposed film webs, and that a first film web (70) is wider than a second film web (70') as the first film web has a peripheral area (76) that is folded for formation of a bottom of the bag, and which is welded together with the first film web (70). 
Vrećice u traci prema zahtjevu 1 ili 2, naznačene time što vrećice u traci obuhvaćaju dvije trake od folije postavljene jedna iznad druge, te da je prva traka od folije (70) šira od druge trake od folije (70') dok prva traka od folije ima rubno područje (76) koje je preklopljeno radi oblikovanja dna vrećice, a koje je međusobno zavareno s prvom trakom od folije (70).
Bag web according to claim 7, characterised in that the additional film pieces forming the sides (46) extend from the bottom of the bag to a position adjacent to the zipper parts. 
Vrećice u traci prema zahtjevu 7, naznačene time što se dodatni dijelovi folije koji tvore strane (46) protežu od dna vrećice do mjesta koje se nalazi pored dijelova zatvarača.
Bag web according to any preceding claim, characterised in that the bag web is provided with a central support region (42) extending longitudinally of the bag web, the central support region connecting bag items (12) that are disposed side by side transversely of the web, the central support region being conveyed on the support rail (20) along the conveyor path through the filling station (44), and that it is the peripheral areas at the outermost opposite bag opening edges of two juxtaposed bag items that are brought in guiding connection with the guide means. 
Vrećice u traci prema bilo kojem prethodnom zahtjevu, naznačene time što je vrećica u traci predviđena sa središnjim nosivim područjem (42) koje se proteže uzdužno od vrećice u traci, te središnje nosivo područje povezuje elemente vrećice (12) koji su postavljeni jedan do drugoga poprečno na traku, te se središnje nosivo područje transportira na nosivoj tračnici (20) uzduž putanje transportne trake kroz postaju za punjenje (44), te da se periferna područja na najudaljenijim suprotnim rubovima otvora vrećice dvaju suprotstavljenih elemenata vrećice dovode u spojni kontakt sa sredstvima za vođenje.
two film webs (70, 70')that are to form front and back sides of the bags are provided along their opening edges with peripheral strip areas, in which a series of holes or corresponding star perforations are formed; 
dvije trake od folije (70, 70') koje su namijenjene da tvore prednje i stražnje strane vrećica predviđene su uzduž njihovih otvorenih rubova s rubnim područjima trake, u kojima su oblikovani nizovi rupica ili odgovarajućih zvjezdastih perforacija;
the continuous web of bag items is conveyed through a filling station in which the bag openings are kept open for receiving filling material; 
neprekidna traka elemenata vrećica se transportira kroz stanicu za punjenje u kojoj se otvori na vrećici drže otvorenim radi prihvata materijala kojim se pune;
the bag opening edges are joined again after filling the bags for closing the bags; 
otvoreni rubovi vrećice se ponovno spajaju nakon punjenja vrećice radi zatvaranja vrećice;
the bags are closed after passing through the filling station and separated from the web. 
vrećice se zatvaraju nakon prolaska kroz stanicu za punjenje i odvajaju od trake.
Method according to any of claims 11-14, characterised in that the bag web is provided with a central support region (42) extending longitudinally of the bag web, the central support region connecting bag items (12) that are disposed side by side transversely of the web, that the central support region is conveyed on the support rail along the conveyor path through the filling station (44), and that it is the peripheral areas at the outermost opposite bag opening edges of two juxtaposed bag items that are brought in guiding connection with the guide means. 
Postupak prema bilo kojem od zahtjeva 11-14, naznačen time što je vrećica u traci predviđena sa središnjim nosivim područjem (42) koje se proteže uzdužno od vrećice u traci, središnje nosivo područje povezuje elemente vrećice (12) koji su postavljeni jedan do drugoga poprečno na traku, te se središnje nosivo područje transportira na nosivoj tračnici uzduž putanje transportera kroz postaju za punjenje (44), i da se periferna područja na najudaljenijim suprotnim rubovima otvora vrećice dvaju združenih elemenata vrećice dovode u spojni kontakt sa sredstvima za vođenje.
Method according to claim 16, characterised in that the film web is used optionally for making one or two bag webs. 
Postupak prema zahtjevu 16, naznačen time što se traka od folije koristi po izboru za izradu jedne ili dvije vrećice u traci.
a water-suspended microparticulate calcite mineral with a particle diameter ≤35, wherein the content of the microparticulate calcite mineral in water lies in the range from 100 g/L to 1,000 g/L, 
mikropartikulirani mineral kalcit suspendiran u vodi s promjerom čestica ≤ 35 µm, gdje se sadržaj mikropartikuliranog kalcitnog materijala u vodi kreće u rasponu od 100 g/l do 1000 g/l,
The aqueous suspension preparation of claim 1, wherein the content of the microparticulate calcite mineral in water lies in the range from 400 g/L to 750 g/L. 
Pripravak u obliku vodene suspenzije u skladu s patentnim zahtjevom 1, naznačen time što se sadržaj mikropartikuliranog minerala kalcita u vodi kreće u rasponu od 400 g/l do 750 g/l.
The aqueous suspension preparation of claim 1, wherein the proportion of the plant extract in the aqueous suspension preparation is from 10% to 20%, calculated as a percentage of the water-suspended microparticulate calcite mineral. 
Pripravak u obliku vodene suspenzije u skladu s patentnim zahtjevom 1, naznačen time što je udio biljnog ekstrakta u njemu od 10 % do 20 %, izračunato kao udio mikropartikuliranog minerala kalcita suspendiranog u vodi.
g/L to 750 g/L of the water-suspended microparticulate calcite mineral; 
g/l do 750 g/l mikropartikuliranog minerala kalcita suspendiranog u vodi;
10% to 20% of the plant extract, calculated as a fraction of the water-suspended microparticulate calcite mineral; and 
% do 20 % biljnog ekstrakta, izračunato kao udio mikropartikuliranog minerala kalcita suspendiranog u vodi; i
in a transfer phase following the mixing phase: 
u fazi prijenosa nakon faze miješanja:
in an injection phase following the transfer phase, injecting the bone cement. 
u fazi injiciranja nakon faze prijenosa, injiciranju koštanog cementa.
The composition according to claim 1 comprising about 2 mg to about 4 mg of buprenorphine. 
Pripravak sukladno patentnom zahtjevu 1 sadrži 2 mg do 4 mg buprenorfina.
The composition according to claim 1 comprising about 1.0 to about 4 mg of Compound-1. 
Pripravak sukladno patentnom zahtjevu 1 sadrži 1,0 do 4 mg Spoja-1.
The composition according to claim 1 comprising about 2 mg to about 8 mg of buprenorphine. 
Pripravak sukladno patentnom zahtjevu 1 sadrži 2 do 8 mg buprenorfina.
A composition as defined in any one of claims 1 to 9 for use in a method of treating a depressive disorder, wherein Compound-1 has the structure: 
Pripravak sukladno bilo kojem od patentnim zahtjeva od 1 do 9 za uporabu u postupku liječenja depresivnog poremećaja, pri čemu taj Spoj- 1 sadrži strukturu:
The composition for use according to claim 10, wherein said depressive disorder is selected from major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression; premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder. 
Pripravak sukladno patentnom zahtjevu 10, naznačeno time, da je navedeni depresivni poremećaj odabran iz većeg depresivnog poremećaja, kronične depresije, ozbiljnih unipolarnih periodičnih većih depresivnih epizoda, distimijskog poremećaja, depresivne neuroze i neurotske depresije, melankolične depresije, atipične depresije, reaktivne depresije, depresije otporne na liječenje, sezonskog afektivnog poremećaja i pedijatrijske depresije; predmenstrualnog sindroma, predmenstrualnog disforičnog poremećaja, valunga, bipolarnog poremećaja ili manične depresije, bipolarnog poremećaja tip I, bipolarnog poremećaja tip II i ciklotimnog poremećaja.
The composition for use according to claim 10, wherein said depressive disorder is major depressive disorder. 
Pripravak za uporabu sukladno patentnom zahtjevu 10, naznačeno time, da je navedeni depresivni poremećaj klinička depresija.
A plow (300) according to claim 7, longitudinal vertical cross-sections of said surface (79) being concave. 
Plug (300) u skladu s patentnim zahtjevom 7, naznačen time što su uzdužni okomiti poprečni presjeci navedene površine (79) udubljeni.
A plow (300) according to claim 9 further comprising keel plates (370), said blade (310) having at least two said keel plates (370) spaced apart and extending thereunder. 
Plug (300) u skladu s patentnim zahtjevom 9, naznačen time što dodatno ima ploče kobilice (370), gdje navedena oštrica (310) ima najmanje dvije navedene ploče kobilice (370), koje su međusobno razmaknute i pružaju se ispod nje.
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in ameliorating or treating a viral infection caused by a virus selected from the group consisting of a human parainfluenza virus 3 and a human metapneumovirus, wherein the compound of Formula (I) has the structure: wherein: 
Spoj s Formulom (I), ili njegova farmaceutski prihvatljiva sol, za upotrebu u ublažavanju ili liječenju virusne infekcije uzrokovane virusom koji je odabran iz skupine koju čine humani parainfluenca virus tip 3 i humani metapneumovirus, pri čemu spoj s Formulom (I) ima strukturu: pri čemu:
B1A is selected from the group consisting of: 
A je odabran iz skupine koja sadrži:
RA2 is selected from the group consisting of hydrogen, halogen and NHRJ2, wherein RJ2 is selected from the group consisting of hydrogen, -C(=O)RK2 and - C(=O)ORL2; 
RA2 je odabran iz skupine koja sadrži vodik, halogen i NHRJ2, pri čemu RJ2 je odabran iz skupine koja sadrži vodik, -C(=O)RK2 i - C(=O)ORL2;
RB2 is halogen or NHRW2, wherein RW2 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C3-8 cycloalkyl, -C(=O)RM2 and -C(=O)ORN2; 
RB2 je halogen ili NHRW2, pri čemu RW2 je odabran iz skupine koja sadrži vodik, po izboru supstituiran C1-6 alkil, po izboru supstituiran C2-6 alkenil, po izboru supstituiran C3-8 cikloalkil, -C(=O)RM2 i -C(=O)ORN2;
RE2 is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C1-6 alkyl, an optionally substituted C3-8 cycloalkyl, -C(=O)RR2 and - C(=O)ORS2; 
RE2 je odabran iz skupine koja sadrži vodik, hidroksi, po izboru supstituiran C1-6 alkil, po izboru supstituiran C3-8cikloalkil, -C(=O)RR2 i - C(=O)ORS2;
and Y3 are independently N or CRI2, wherein RI2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6-alkyl, an optionally substituted C2-6-alkenyl and an optionally substituted C2-6-alkynyl; 
i Y3 su neovisno N ili CRI2, pri čemu RI2 je odabran iz skupine koja sadrži vodik, halogen, po izboru supstituiran C1-6-alkil, po izboru supstituiran C2-6-alkenil i po izboru supstituiran C2-6-alkinil;
R2A is selected from the group consisting of an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl, an alkoxy substituted C1-6 alkyl, a sulfenyl substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C2-6 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted -O-C1-6 alkyl, an optionally substituted -O-C3-6 alkenyl, an optionally substituted -O-C3-6 alkynyl and cyano; 
A je odabran iz skupine koja sadrži nesupstituirani C1-6alkil, halogen supstituirani C1-6 alkil, hidroksi supstituirani C1-6alkil, alkoksi supstituirani C1-6 alkil, sulfenil supstituirani C1-6alkil, po izboru supstituiran C2-6 alkenil, po izboru supstituiran C2-6 alkinil, po izboru supstituiran C3-6 cikloalkil, po izboru supstituiran -O-C1-6 alkil, po izboru supstituiran -O-C3-6 alkenil, po izboru supstituiran -O-C3-6 alkinil i cijano;
R3A is selected from the group consisting of OH, -OC(=O)R"A and an optionally substituted O-linked amino acid; 
A je odabran iz skupine koja sadrži OH, -OC(=O)R"A i po izboru supstituiranu O-vezana aminokiselina;
R6A, R7A and R8A are independently selected from the group consisting of absent, hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C1-6 alkyl), an optionally substituted *-(CR15AR16A)p-O-C1-24 alkyl, an optionally substituted *-(CR17AR18A)p-O-C1-24 alkenyl, or 
A, R7A i R8A su neovisno odabrani iz skupine koja sadrži odsutno, vodik, po izboru supstituiran C1-24alkil, po izboru supstituiran C2-24 alkenil, po izboru supstituiran C2-24 alkinil, po izboru supstituiran C3-6 cikloalkil, po izboru supstituiran C3-6 cikloalkenil, po izboru supstituiran aril, po izboru supstituiran heteroaril, po izboru supstituiran aril(C1-6 alkil), po izboru supstituiran *-(CR15AR16A)p-O-C1-24 alkil, po izboru supstituiran *-(CR17AR18A)p-O-C1-24 alkenil, ili
R9A is selected from the group consisting of an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl, NR30AR31A, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; 
A je odabran iz skupine koja sadrži po izboru supstituiran C1-24 alkil, po izboru supstituiran C2-24 alkenil, po izboru supstituiran C2-24 alkinil, po izboru supstituiran C3-6cikloalkil, po izboru supstituiran C3-6 cikloalkenil, NR30AR31A, po izboru supstituirana N-vezana aminokiselina i po izboru supstituirani esterski derivat N-vezane aminokiseline;
R19A, R20A, R22A and R23A are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl; 
A, R20A, R22A i R23A su neovisno odabrani iz skupine koja sadrži vodik, po izboru supstituiran C1-24 alkil i po izboru supstituiran aril;
R25A and R29A are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl; 
A i R29A su neovisno odabrani iz skupine koja sadrži vodik, po izboru supstituiran C1-24 alkil i po izboru supstituiran aril;
R26A and R27A are independently -C=N or an optionally substituted substituent selected from the group consisting of C2-8 organylcarbonyl, C2-8 alkoxycarbonyl and C2-8 organylaminocarbonyl; 
A i R27A su neovisno -C=N ili po izboru supstituiran supstituent odabran iz skupine koja sadrži C2-8organilkarbonil, C2-8 alkoksikarbonil i C2-8organilaminokarbonil;
p and q are independently selected from the group consisting of 1, 2 and 3; 
p i q su neovisno odabrani iz skupine koja sadrži 1, 2 i 3;
The compound, or a pharmaceutically acceptable salt thereof, for the use of Claim 3, wherein R6A and R7A are both hydrogen; or wherein R6A and R7A are both absent; or R1A is wherein R6A is preferably m is 0; and wherein R7A, R12A and R13A are independently absent or hydrogen; or preferably m is 1; and wherein R7A, R12A, R13A and R14A are independently absent or hydrogen. 
Spoj, ili njegova farmaceutski prihvatljiva sol, za upotrebu prema zahtjevu 3, naznačen time što R6A i R7A su oba vodik; ili pri čemu R6Ai R7A su oba odsutni; ili R1A je pri čemu R6A je poželjno m je 0; i pri čemu R7A, R12A i R13A su neovisno odsutni ili vodik; ili poželjno m je 1; i pri čemu R7A, R12A, R13Ai R14A su neovisno odsutni ili vodik.